From trial-ready registries to genotyping parties, the field has developed new techniques and meds to stem a tide of failed trials. Alzforum’s 13-part series sums up the state of the art as presented at a recent conference.

This past decade, Alzheimer’s science has undergone a paradigm shift toward the disease’s early, silent phase. For trials, this means change at every level: new participants, new screening tools, new outcome measurements. What’s the progress?

A new study shows that people with a protective Aβ mutation have less of the peptide in their blood all through their lives, likely explaining why they do not get Alzheimer's. It suggests ways to prevent the disease in the vast majority of people who don’t have the mutation.

A founder of U.S. Alzheimer’s research, Robert D. Terry, has died at 93. He first showed what plaques and tangles look like in the electron microscope, and linked failing cognition to withering synapses in the brain.

As researchers seek cognitively normal people on the way to Alzheimer’s to fill clinical prevention trials, they face the delicate task of disclosing a highly elevated, but not certain, risk of developing the disease to thousands of people. Scientists look to cancer research for cues as they recruit for the first of such trials.

The Dominantly Inherited Alzheimer’s Network is churning out serial data on how Alzheimer’s disease develops in a given person over many years, and at the same time transforming how therapeutic trials are being done on this disease.